HilleVax is a biopharmaceutical company focused on the development and commercialisation of novel vaccine candidates. Its initial programme, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. Norovirus is a common intestinal infection marked by diarrhoea, vomiting, abdominal cramps, nausea and sometimes fever that may lead to clinically significant dehydration.

LocationBoston, MA
CEORob Hershberg
Partner Andrew Sinclair
Websitewww.hillevax.com